The PMPRB has extended the deadline for comments on the revised draft Guidelines to August 4, 2020.
See here for further details on the change. Please also see our June 23, 2020 article for a summary of notable changes in the revised draft Guidelines.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
PMPRB news: New Vice Chairperson appointed, Meds Entry Watch 7th Ed. published
On August 15, 2023, the Minister of Health announced the appointment of Anie Perrault as Vice Chairperson of the Patented Medicine Prices Review Board (PMPRB) for a five-year term.Read More -
pCPA announces new three-year pricing initiative agreement for generic drugs with CGPA, appointment of Douglas Clark as its first CEO
The pan-Canadian Pharmaceutical Alliance (pCPA) has appointed Douglas Clark as the pCPA’s first CEO, effective September 11, 2023.Read More -
CADTH releases 2022-2023 annual report
On August 3, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) released its annual report.Read More